---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-007415"
form_type: "8-K"
ticker: "APTOF"
cik: "0000882361"
company_name: "Aptose Biosciences Inc."
filed_at: "2025-11-19T23:59:59+00:00"
generated_at: "2026-05-16T18:39:17.819232+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Aptose to be acquired by Hanmi Pharmaceutical at C$2.41/share, 28% premium to 30-day VWAP

## Summary
- Hanmi already owns 19.93% and provided >US$30M in debt facilities over 18 months.
- Transaction requires approval of 2/3 of votes, plus minority approval; special meeting by Jan 16, 2026.
- Formal valuation by Locust Walk: fair market value range of C$1.00 to C$5.23 per share.
- Aptose will be delisted from TSX and cease Canadian reporting obligations after closing.
- Officers and directors have entered voting support agreements in favor of the arrangement.

## SEC filing metadata
- accession: 0001171843-25-007415
- form_type: 8-K
- ticker: APTOF
- cik: 0000882361
- company_name: Aptose Biosciences Inc.
- filed_at: 2025-11-19T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882361/000117184325007415/0001171843-25-007415-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882361/000117184325007415/f8k_111925.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-007415
- JSON: https://secwatch.observer/filing/0001171843-25-007415.json
- Plain text: https://secwatch.observer/filing/0001171843-25-007415.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.